|
Leicester among world first in novel cancer prevention trial
November 04, 2002University of Leicester team pioneers tests of new drug with ‘red wine compound’
Leicester has been selected as one of the first centres in the world to trial a revolutionary new cancer prevention drug, based on a natural compound found in red wine. This will form a major part of the cancer prevention research at the University of Leicester.
Cancer researchers from the University’s Department of Oncology, based at the Leicester Royal Infirmary, have been awarded just over £1 million sterling ($1.7 million) along with the University of Michigan. The award, from the US National Cancer Institute (NCI), the major US government body which funds and co-ordinates cancer research, is the first time that a group outside America has been funded by the NCI for the early clinical development of a drug that may prevent cancer.
The money will be used by the Cancer Biomarker and Prevention Group of the University of Leicester, in conjunction with the Comprehensive Cancer Centre at the University of Michigan, to conduct preclinical and clinical evaluation of resveratrol, a natural compound found in red wine.
Professor Will Steward, of the University of Leicester, said: “Resveratrol is a natural agent found in grapes, peanuts and several berries. It is present in fruit juice from these berries and in wine. Consumption of resveratrol has been proposed as one possible explanation for the low incidence of cardiovascular disease in Southern European countries with high red wine consumption, and resveratrol has been shown to possess anti-inflammatory and anti-cancer activity in experimental models.”
“Since resveratrol may be of value in preventing cancer, the NCI are funding early clinical studies of pure resveratrol capsules in healthy volunteers and patients with early cancer. These studies will be conducted in Leicester and at the University of Michigan.”
The principal investigators, in the UK are Professors William Steward, Andreas Gescher and Peter Farmer and Drs David Boocock, David Hemingway and Ricky Sharma.
Professor Steward added: “Over the past four years, the University of Leicester has built up the largest integrated cancer prevention group in Europe. Laboratory-based scientists and clinicians work closely together to develop novel drugs which have promise for reducing the risk of developing cancer. This award is a major advance and we hope it will enable us to take resveratrol forward to become a valuable agent to reduce the number of people who develop cancer in the future.”
The research group attracted international publicity a few years ago when they investigated the cancer-fighting properties of curcumin, an ingredient in curries.
Professor Steward said: “The Leicester team has been involved with the early clinical development of the potential cancer preventive agent curcumin, derived from the dietary spice turmeric. Encouraging results are being obtained from this. The Cancer Biomarker and Prevention Group are also planning early clinical development of other dietary constituents that may help in the fight against cancer.”
The principal investigator in the USA, Professor Dean Brenner, said: “The award of this competitive grant by the US NCI is a major achievement. In the USA, such awards are given only to teams who are able to successfully integrate their laboratory research scientists with clinical investigators, and awards made to teams outside the US are rare.”
“Foreign awards are given only to groups who are able to provide expertise not available in the USA. The successful completion of this contract signifies that the University of Leicester group is considered a world class translational research group and I am thrilled to be able to work closely with such an outstanding group.”
FACTFILE
Can patients with cancer take part?
- No, the initial trial has to be with healthy volunteers
When will the trials begin?
- The trials will begin in Spring 2003
Where will they take place?
- University of Leicester and Leicester Royal Infirmary
How will people know when the trial is about to start?
- Flyers will be distributed in the University of Leicester and Leicester Royal Infirmary
How will people be selected for the trials?
- Selection made from completed information on flyers of healthy, mainly young volunteers, a 50/50 split males and females.
Leicester, University of
The money will be used by the Cancer Biomarker and Prevention Group of the University of Leicester, in conjunction with the Comprehensive Cancer Centre at the University of Michigan, to conduct preclinical and clinical evaluation of resveratrol, a natural compound found in red wine.
Professor Will Steward, of the University of Leicester, said: “Resveratrol is a natural agent found in grapes, peanuts and several berries. It is present in fruit juice from these berries and in wine. Consumption of resveratrol has been proposed as one possible explanation for the low incidence of cardiovascular disease in Southern European countries with high red wine consumption, and resveratrol has been shown to possess anti-inflammatory and anti-cancer activity in experimental models.”
“Since resveratrol may be of value in preventing cancer, the NCI are funding early clinical studies of pure resveratrol capsules in healthy volunteers and patients with early cancer. These studies will be conducted in Leicester and at the University of Michigan.”
The principal investigators, in the UK are Professors William Steward, Andreas Gescher and Peter Farmer and Drs David Boocock, David Hemingway and Ricky Sharma.
Professor Steward added: “Over the past four years, the University of Leicester has built up the largest integrated cancer prevention group in Europe. Laboratory-based scientists and clinicians work closely together to develop novel drugs which have promise for reducing the risk of developing cancer. This award is a major advance and we hope it will enable us to take resveratrol forward to become a valuable agent to reduce the number of people who develop cancer in the future.”
The research group attracted international publicity a few years ago when they investigated the cancer-fighting properties of curcumin, an ingredient in curries.
Professor Steward said: “The Leicester team has been involved with the early clinical development of the potential cancer preventive agent curcumin, derived from the dietary spice turmeric. Encouraging results are being obtained from this. The Cancer Biomarker and Prevention Group are also planning early clinical development of other dietary constituents that may help in the fight against cancer.”
The principal investigator in the USA, Professor Dean Brenner, said: “The award of this competitive grant by the US NCI is a major achievement. In the USA, such awards are given only to teams who are able to successfully integrate their laboratory research scientists with clinical investigators, and awards made to teams outside the US are rare.”
“Foreign awards are given only to groups who are able to provide expertise not available in the USA. The successful completion of this contract signifies that the University of Leicester group is considered a world class translational research group and I am thrilled to be able to work closely with such an outstanding group.”
FACTFILE
Can patients with cancer take part?
- No, the initial trial has to be with healthy volunteers
When will the trials begin?
- The trials will begin in Spring 2003
Where will they take place?
- University of Leicester and Leicester Royal Infirmary
How will people know when the trial is about to start?
- Flyers will be distributed in the University of Leicester and Leicester Royal Infirmary
How will people be selected for the trials?
- Selection made from completed information on flyers of healthy, mainly young volunteers, a 50/50 split males and females.
Leicester, University of
Cancer News and Current Cancer Events RSSCrossed (Evolutionary) Signals?
What do humans and single-celled choanoflagellates have in common? More than you'd think. New research into the choanoflagellate genome shows these ancient organisms have similar levels of proteins that cells in more complex organisms, including humans, use to communicate with each other.
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston.
'Hibernation-on-demand' drug significantly improves survival after extreme blood loss
For the first time, researchers have demonstrated that the administration of minute amounts of inhaled or intravenous hydrogen sulfide, or H2S - the molecule that gives rotten eggs their sulfurous stench - significantly improves survival from extreme blood loss in rats.
Effects of Healing Touch Therapy Being Studied
Often, a gentle hand on your shoulder when you're upset is all it takes to ease your mind and calm your nerves.
New paper offers insights into 'blinking' phenomena
A new paper by a team of researchers led by University of Notre Dame physicist Bolizsár Jankó provides an overview of research into one of the few remaining unsolved problems of quantum mechanics.
Sunburn alert: UVB does more damage to DNA than UVA
As bombs burst in air this July 4, chances are that sunburn will be the red glare that most folks see - and feel. But unfortunately, even when there is no burn, the effects of the sun's ultraviolet (UV) rays can have deadly consequences.
Happiness is rising around the world: U-M study
People in most countries around the world are happier these days, according to newly released data from the World Values Survey based at the University of Michigan Institute for Social Research.
Zinc finger proteins put personalized HIV therapy within reach
Researchers at the University of Pennsylvania School of Medicine and collaborators are using minute, naturally occurring proteins called zinc fingers to engineer T cells to one day treat AIDS in humans.
Plants in the fourth dimension
As anyone who has suffered from jetlag knows, we have internal clocks that tell us when to sleep and wake, and we can be miserable when these are disrupted.
Spiritual effects of hallucinogens persist, Johns Hopkins researchers report
In a follow-up to research showing that psilocybin, a substance contained in "sacred mushrooms," produces substantial spiritual effects, a Johns Hopkins team reports that those beneficial effects appear to last more than a year.
More Cancer News Articles
 | The Last Lecture by Randy Pausch, Jeffrey Zaslow |
 | The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health by T. Colin Campbell, Thomas M. Campbell II |
 | My Sister's Keeper: A Novel by Jodi Picoult |
 | Eat to Live: The Revolutionary Formula for Fast and Sustained Weight Loss by Joel Fuhrman |
 | Crazy Sexy Cancer Tips by Kris Carr |
 | Six Innings by James Preller |
 | Silent Spring by Rachel Carson |
 | Good Calories, Bad Calories by Gary Taubes |
 | Apples and Oranges: My Brother and Me, Lost and Found by Marie Brenner |
 | It's Not About the Bike: My Journey Back to Life by Lance Armstrong, Sally Jenkins |
| © 2008 BrightSurf.com |